Cite

HARVARD Citation

    Verstockt, B. et al. (n.d.). A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases. Expert opinion on drug safety. 16 (7), pp. 809-821. [Online]. 
  
Back to record